Clinical Trial Update: To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of osimertinib given before chemoradiation and as maintenance therapy in patients with Stage III unresectable n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (Tagrisso) (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING